Bridging the Gaps Between Research, Medicine, and the Patient

FATTY LIVER FOUNDATION



Organization Presentation





To improve the diagnosis, treatment and support of Americans with fatty liver, NAFLD or NASH through

awareness, education, screening and patient advocacy.







Raise awareness on the existence, prevalence, causes, and threat of NAFLD or NASH in persons at risk for their hepatic, metabolic, and cardiovascular complications.



Educate patients about NAFLD/NASH and the dietary and lifestyle approaches that can slow, halt, or reverse its progression.

> Facilitate awareness among diagnosed patients about ongoing FDA-approved, clinical therapeutic trials that they may want to consider.



Our Goals



Develop a wellness screening program to identify persons at risk that have progressive, but asymptomatic liver disease.







Why Us?

WE ARE THE ONLY NATIONAL PATIENT VOICE DEALING WITH NASH ON THE GROUND.



NASH – A Gathering Storm

NASH is 21st Century's looming public health threat.

The annual cost of inaction associated with all cases of NAFLD were estimated at \$103 billion in the U.S¹.


To date, **no medicines** have been approved for the treatment of NASH.

1. Younossi ZM, Blissett D, Blissett R, et al. 2016. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Journal of Hepatology 64(5): 1577-86.

It is expected to be the leading cause of liver transplantation in the as early as next year. U.S.

> Widespread variation in diagnosis & care due to lack of consensus among existing clinical practice guidelines.


Poor health system preparedness to provide appropriate multi-disciplinary care for people with NAFLD & NASH to meet growing needs for liver transplantation.



Tip of the Iceberg of a Silent & Gigantic Epidemic

~180,000 Diagnosed NASH Patients

>100 million Americans who are unaware of NAFLD and NASH remain undiagnosed.



~3,000 Randomized in clinical trials (80% screen/fail rate)

To Combat NASH Epidemic, FLF Focused on the Areas Where Your Donations Can Have the Most Impact

Public Communications

Patient Advocacy



¢,





Public Communications

FLF believes the patient voice is the most authentic to reach high risk and vulnerable communities.

customized and contextualized communications.



- FLF will expand use of multi-media platforms to educate, raise awareness and influence healthy lifestyles with





FLF will normalize the voice of patients in medical, public health, policy, financing, and research and development arenas.

as the standard of patient engagement.

Patient Advocacy



This is being recorded in the Liver Patients Manifesto





Screening

Building on the tried and tested models of communitybased screening, FLF is leveraging other networks of at-risk populations to scale-up liver health screening to one million people per year and routinizing it as public health intervention.

Our methodology builds trust and creates the *"teachable moment"* to effect change and modify risk.








FLF is consolidating an evidence-based, patient-led lifestyle package, that will promote, inspire, and enable liver health lifestyle choices.

Lifestyle







Advisory Group experts & people living with NASH.



Your donation is quickly deployed to strengthen our organizational capacity & support programs executed by FLF team & our collaborators.



We utilize our program & financial expertise to compile & analyze data, measure progress, evaluate project outcomes & impact.



We share & communicate the collective impact, successes & challenges with our donors, collaborators, and the NASH community.








We Have Proven That We Can Identify At-Risk Patients


SUNN Study (Screening for Undiagnosed NAFLD AND NASH) Partial results 602 patients


ClinicalTrials.gov NCT03726827

Identifying asymptomatic undiagnosed patients and educating them about NASH and NAFLD as well as providing them with information about clinical trials and access to care.



Impact of Public Communications & Engagements








FLF plans to develop multiple collaborative channels of outreach and services focused on improving the lives of patients by providing services to bridge the gaps from wellness to death as a result of noncommunicable diseases, of which NASH is central, as **THE VOICE OF NASH**.

Bridging the gaps between Research, Medicine, and the Patients.



Meet Our Team



Wayne Eskridge **Co-Founder & CEO**



Rosemary Wickowski Co-Founder & COO



Wayne Gosbee **Project Manager**



Neeraj Mistry, MD, MPH **Chief Medical Officer**



Henry E. Chang Strategic Engagement & Development



Laura Mosley FibroScan® Certified RN



May-Linh Huynh Data Analyst

Wayne Eskridge co-founder & ceo

66 My mission - To save my life. When I learned that there was no treatment for my disease and wouldn't be without clinical trials, which are impossible without patients, I decided to get more patients who could be in those trials by sponsoring screening.





Our Medical Advisory Group







Director of Liver Transplant Program Houston Methodist Transplant Center Houston, TX

Robert A. Fisher, MD

Professor & Chief of Transplant Surgery Beth Israel Deaconess Medical Center Boston, MA

Meagan Gray, MD

Transplant Hepatologist University of Alabama at Birmingham *Birmingham, AL*

Nadege Gunn, MD

Gastroenterologist & Hepatologist Austin Gastroenterology & Pinnacle Research *Austin, TX*










Grace Terrell, MD, FACP

CEO, Envision Genomics, Inc. General Internist, Cornerstone Internal Medicine *High Point, NC*



Brent A. Tetri, MD

Professor Internal Medicine | Gastroenterologist SLU Care Physician Group *St. Louis, MO*



John M. Vierling, MD, FACP

Professor of Medicine & Surgery Chief of Hepatology, Baylor College of Medicine *Houston, TX*



Theodore Walters, MD


Medical Oncologist/Hematologist St. Luke's Mountain States Tumor Institute Boise, ID

Our Donors, Partners & Collaborators





Our Presence on the Ground*





Team Member



Medical Advisory Group



 \checkmark

Corporate Partner

Non-Profit Collaborator

*As of October 2019



Thank You!

